ArticleFrontiers in pharmacology2022
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles: A Systematic Review.JAMA network open · 2023Pooled it
- Ameliorative effects of Spirulina platensis niosome and Echinacea purpura on cyclophosphamide-induced splenic, cardiac and neurotoxicity via modulating NF-κB pathway and oxidative stress.Scientific reports · 2026Article
- Evaluating the antiviral efficacy and specificity of chlorogenic acid and related herbal extracts against SARS-CoV-2 variants via spike protein binding intervention.Journal of traditional and complementary medicine · 2025Article
- Critical analysis of Echinacea preparations marketed in Germany.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Herbal and Dietary Supplements as Adjunctive Treatment for Mild SARS-CoV-2 Infection in Italy.Nutrients · 2025Review
- Exploring the potency of polyphenol-rich blend fromHeliyon · 2024Article
- Echinacea Reduces Antibiotics by Preventing Respiratory Infections: A Meta-Analysis (ERA-PRIMA).Antibiotics (Basel, Switzerland) · 2024Review
- Volatile Composition, Antimicrobial Activity, and In Vitro Innate Immunomodulatory Activity ofMolecules (Basel, Switzerland) · 2023Article
- ECHOPvir: A Mixture of Echinacea and Hop Extracts Endowed with Cytoprotective, Immunomodulatory and Antiviral Properties.Nutrients · 2023Article
- Natural Products for the Prevention and Treatment of Common Cold and Viral Respiratory Infections.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Natural Ingredients to Improve Immunity.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Novel Echinacea formulations for the treatment of acute respiratory tract infections in adults-A randomized blinded controlled trial.Frontiers in medicine · 2023Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 vaccination is effective in preventing severe Covid-19, but efficacy in reducing viral load and transmission wanes over time. In addition, the emergence of novel SARS-CoV-2 variants increases the threat of uncontrolled dissemination and additional antiviral therapies are urgently needed for effective containment. In previous
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.